drugset / Trial / NCT06919939
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether combining Loncastuximab Tesirine with Epcoritamab is tolerable and effective for reducing and/or eliminating lymphoma cells in the body.
Timeline
- Start
- 2026-01-07
- Primary completion
- 2031-01-07
- Completion
- 2031-01-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epcoritamab | Monoclonal antibody | 48 mg | Subcutaneous |
| Subject | Loncastuximab Tesirine | Other / unclassified | 75 ug/kg | Intravenous |